Mesa Laboratories Inc /Co/ (MLAB) Stock Price & Analysis
Mesa Laboratories Inc /Co/ (MLAB) fell 3.42% to USD 97.5 as of July 25, 2026 at 05:08 UTC, according to Nexqual real-time market data.
MLAB last closed at USD 100.95; the session ranged USD 96.43–101.54 on volume of 120,112 shares. Market capitalization is $538.68M, with a 52-week range of USD 55.45–113.99 (NMS). Source: Nexqual, July 25, 2026 at 05:08 UTC.
Key Statistics (as of July 25, 2026 at 05:08 UTC)
| Price | USD 97.5 |
|---|---|
| Change | ▼ 3.42% (down) |
| Previous Close | USD 100.95 |
| Open | USD 101.54 |
| Day Range | USD 96.43 – 101.54 |
| 52-Week Range | USD 55.45 – 113.99 |
| Volume | 120,112 shares |
| Market Cap | $538.68M |
| Exchange | NMS |
Technical Analysis (MLAB)
Nexqual's technical model rates MLAB "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.91 (neutral) |
| vs SMA50 | Below (USD 100.53) |
| MACD | -0.55 (negative) |
Analyst Ratings (MLAB)
Wall Street analysts rate MLAB "None" based on 2 analysts, with a mean price target of USD 112 (range USD 94–130), per Nexqual as of July 25, 2026 at 05:08 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 112 |
| High Target | USD 130 |
| Low Target | USD 94 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (MLAB)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD 2.55 |
| Revenue Estimate | $60.87M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.83 vs est 1.39 ▲ beat |
| 2025-12-31 | USD 1.76 vs est 1.47 ▲ beat |
| 2025-09-30 | USD 2.11 vs est 1.56 ▲ beat |
| 2025-06-30 | USD 1.88 vs est 2.16 ▼ miss |
Source: Nexqual, July 25, 2026 at 05:08 UTC.
Financials & Fundamentals (MLAB)
| Total Revenue | $249.13M |
|---|---|
| Revenue Growth (YoY) | +2.60% |
| Gross Margin | +63.53% |
| Operating Margin | +4.31% |
| Profit Margin | +2.69% |
| ROE | +3.88% |
| Debt / Equity | 90.65 |
| Current Ratio | 1.72 |
| Total Cash | $28.57M |
| Total Debt | $168.83M |
| Free Cash Flow | $31.88M |
Source: Nexqual, July 25, 2026 at 05:08 UTC.
Financial Health Score (MLAB)
Nexqual rates Mesa Laboratories Inc /Co/'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:08 UTC.
| Growth | Mixed — Revenue +3.4% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 4% |
| Balance Sheet | Mixed — $29M cash vs $169M debt |
| Cash Flow | Solid — FCF $32M, 13% margin |
| Efficiency | Weak — ROE 4%, ROA 2.7% |
Ownership (MLAB)
| Insider Ownership | +5.41% |
|---|---|
| Institutional Ownership | +95.05% |
| Shares Outstanding | 5.52M |
| Float | 4.86M |
| Short % of Float | +7.28% |
Source: Nexqual, July 25, 2026 at 05:08 UTC.
Leadership (MLAB)
Mesa Laboratories Inc /Co/ is led by Siddhartha Chandrakant Kadia B.E., M.S. (age 55), CEO, President & Director, per Nexqual as of July 25, 2026 at 05:08 UTC.
| CEO, President & Director | Siddhartha Chandrakant Kadia B.E., M.S. (age 55) |
|---|---|
| VP & CFO | John V. Sakys (age 56) |
Major Backers & Investors (MLAB)
Notable institutional backers of Mesa Laboratories Inc /Co/ include Long Path Partners LP, Boston Partners, Diamond Hill Capital Management Inc, according to Nexqual as of July 25, 2026 at 05:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Long Path Partners LP | 7.25% |
| Boston Partners | 4.8% |
| Diamond Hill Capital Management Inc | 4.79% |
| Select Equity Group LP | 4.22% |
| Ranger Investment Management, L.p. | 3.63% |
| AQR Capital Management, LLC | 3.05% |
| Morgan Stanley | 2.9% |
| Royce & Associates LP | 2.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.29% |
| Vanguard Group | 8.21% |
Source: Nexqual, July 25, 2026 at 05:08 UTC.
From Mesa Laboratories Inc /Co/'s Latest SEC 10-K Filing (filed 2026-06-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
- The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
- This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries.
- The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UTMD | Utah Medical Products, Inc. | USD 67.14 | ▼ 2.96% |
| WINA | Winmark Corporation | USD 332.52 | ▼ 5.53% |
| OFLX | Omega Flex, Inc. | USD 29.55 | ▼ 1.24% |
| CASS | Cass Information Systems, Inc | USD 54.25 | ▲ 3.29% |
| PFIS | Peoples Financial Services Corp | USD 69.44 | ▲ 2.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:08 UTC. This page is informational and not investment advice.